// App-Quantinova.ai

1200 ⋆ : The ileal bile acid transport inhibitor A4250 reduced pruritus and serum bile acid levels in children with cholestatic liver disease and pruritus: final results from a multiple‐dose, open‐label, multinational study

Researchers

Presenter

  • Ekkehard Sturm

Principal Investigators

  • Ulrich Baumann

  • Florence Lacaille

  • Emmanuel Gonzales

  • Henrik Arnell

  • Bjorn Fischler

  • Marianne Hprby Jprgensen

  • Richard J. Thompson

  • Jan Mattsson

  • Mats Ekelund

  • Erik Lindstrom

  • Per-Goran Gillberg

  • Kristina Torfgard

  • Paresh N. Soni

Medical Centers

  • Albireo, Goteborg, Sweden

  • Albireo Pharma, Boston, MA

  • University Children's Hospital, Tubingen, Germany

  • Medizinische Hochschule Hannover, Hannover, Germany

  • Necker-enfants malades hospital, Paris, France

  • University Hospitals of Paris-Sud Bicêtre, Paris, France

  • Astrid Lindgren Childrens Hospital Q2:08, Karolinska University Hospital, Stockholm, Sweden

  • Rigshospitalet, Copenhagen, Denmark

  • Kings College London, London, United Kingdom

Locations

  • Sweden

  • United States

  • Germany

  • France

  • Denmark

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • A4250

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved